Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study
2019 ◽
Vol 6
(8)
◽
pp. e398-e408
◽
2010 ◽
Vol 150
(3)
◽
pp. 303-312
◽
2017 ◽
Vol 182
(3)
◽
pp. 427-429
◽
2015 ◽
Vol 174
(2)
◽
pp. 456-458
◽
2011 ◽
Vol 155
(1)
◽
pp. 128-130
◽